Literature DB >> 34668840

Regulator of Cell Cycle Protein (RGCC/RGC-32) Protects against Pulmonary Fibrosis.

Irina G Luzina1,2, Violeta Rus1,2, Virginia Lockatell1,2, Jean-Paul Courneya3, Brian S Hampton1, Rita Fishelevich1,2, Alexander V Misharin4, Nevins W Todd1,2, Tudor C Badea5,6, Horea Rus1,2, Sergei P Atamas1,2.   

Abstract

Some previous studies in tissue fibrosis have suggested a profibrotic contribution from elevated expression of a protein termed either RGCC (regulator of cell cycle) or RGC-32 (response gene to complement 32 protein). Our analysis of public gene expression datasets, by contrast, revealed a consistent decrease in RGCC mRNA levels in association with pulmonary fibrosis. Consistent with this observation, we found that stimulating primary adult human lung fibroblasts with transforming growth factor (TGF)-β in cell cultures elevated collagen expression and simultaneously attenuated RGCC mRNA and protein levels. Moreover, overexpression of RGCC in cultured lung fibroblasts attenuated the stimulating effect of TGF-β on collagen levels. Similar to humans with pulmonary fibrosis, the levels of RGCC were also decreased in vivo in lung tissues of wild-type mice challenged with bleomycin in both acute and chronic models. Mice with constitutive RGCC gene deletion accumulated more collagen in their lungs in response to chronic bleomycin challenge than did wild-type mice. RNA-Seq analyses of lung fibroblasts revealed that RGCC overexpression alone had a modest transcriptomic effect, but in combination with TGF-β stimulation, induced notable transcriptomic changes that negated the effects of TGF-β, including on extracellular matrix-related genes. At the level of intracellular signaling, RGCC overexpression delayed early TGF-β-induced Smad2/3 phosphorylation, elevated the expression of total and phosphorylated antifibrotic mediator STAT1, and attenuated the expression of a profibrotic mediator STAT3. We conclude that RGCC plays a protective role in pulmonary fibrosis and that its decline permits collagen accumulation. Restoration of RGCC expression may have therapeutic potential in pulmonary fibrosis.

Entities:  

Keywords:  idiopathic pulmonary fibrosis; lung fibrosis; regulator of cell cycle protein; response gene to complement 32 protein; scleroderma lung disease

Mesh:

Substances:

Year:  2022        PMID: 34668840      PMCID: PMC8845131          DOI: 10.1165/rcmb.2021-0022OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   7.748


  49 in total

1.  Response gene to complement 32 promotes vascular lesion formation through stimulation of smooth muscle cell proliferation and migration.

Authors:  Jia-Ning Wang; Ning Shi; Wei-Bing Xie; Xia Guo; Shi-You Chen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-06-02       Impact factor: 8.311

2.  C5a stimulates the proliferation of breast cancer cells via Akt-dependent RGC-32 gene activation.

Authors:  Yi Lu; Xiao-Bo Hu
Journal:  Oncol Rep       Date:  2014-09-17       Impact factor: 3.906

3.  Syndecan-1 promotes lung fibrosis by regulating epithelial reprogramming through extracellular vesicles.

Authors:  Tanyalak Parimon; Changfu Yao; David M Habiel; Lingyin Ge; Stephanie A Bora; Rena Brauer; Christopher M Evans; Ting Xie; Felix Alonso-Valenteen; Lali K Medina-Kauwe; Dianhua Jiang; Paul W Noble; Cory M Hogaboam; Nan Deng; Olivier Burgy; Travis J Antes; Melanie Königshoff; Barry R Stripp; Sina A Gharib; Peter Chen
Journal:  JCI Insight       Date:  2019-08-08

4.  Distinct roles for the A2B adenosine receptor in acute and chronic stages of bleomycin-induced lung injury.

Authors:  Yang Zhou; Daniel J Schneider; Eva Morschl; Ling Song; Mesias Pedroza; Harry Karmouty-Quintana; Thuy Le; Chun-Xiao Sun; Michael R Blackburn
Journal:  J Immunol       Date:  2010-12-13       Impact factor: 5.422

5.  STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity.

Authors:  Won-Il Jeong; Ogyi Park; Svetlana Radaeva; Bin Gao
Journal:  Hepatology       Date:  2006-12       Impact factor: 17.425

6.  RGC-32 is a novel regulator of the T-lymphocyte cell cycle.

Authors:  Cosmin A Tegla; Cornelia D Cudrici; Vinh Nguyen; Jacob Danoff; Adam M Kruszewski; Dallas Boodhoo; Armugam P Mekala; Sonia I Vlaicu; Ching Chen; Violeta Rus; Tudor C Badea; Horea Rus
Journal:  Exp Mol Pathol       Date:  2015-03-11       Impact factor: 3.362

7.  Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway.

Authors:  L Ulloa; J Doody; J Massagué
Journal:  Nature       Date:  1999-02-25       Impact factor: 49.962

8.  Bleomycin delivery by osmotic minipump: similarity to human scleroderma interstitial lung disease.

Authors:  Rebecca Lee; Charles Reese; Michael Bonner; Elena Tourkina; Zoltan Hajdu; Ellen C Riemer; Richard M Silver; Richard P Visconti; Stanley Hoffman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-02-28       Impact factor: 5.464

9.  Systematic Review and Meta-analysis of Pirfenidone, Nintedanib, and Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis.

Authors:  Enrica Di Martino; Alessio Provenzani; Patrizio Vitulo; Piera Polidori
Journal:  Ann Pharmacother       Date:  2020-10-15       Impact factor: 3.154

Review 10.  IL-12 Family Cytokines in Cancer and Immunotherapy.

Authors:  Bhalchandra Mirlekar; Yuliya Pylayeva-Gupta
Journal:  Cancers (Basel)       Date:  2021-01-06       Impact factor: 6.639

View more
  1 in total

1.  Pumping the Brakes on Pulmonary Fibrosis: A New Role for Regulator of Cell Cycle.

Authors:  Loka Raghu Kumar Penke; Gina Torres Matias; Megan N Ballinger
Journal:  Am J Respir Cell Mol Biol       Date:  2022-02       Impact factor: 6.914

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.